Logo

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

Share this

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

Shots:

  • The approval is based on the P-III CheckMate -274 trial evaluating Opdivo (240mg- IV- q2w- for ~1 yrs.) vs PBO in a ratio (1:1) in 709 patients with UC who are at high risk of recurrence after undergoing radical resection
  • The results showed a 30% reduction in the risk of disease recurrence or death- m-DFS (20.8 vs 10.8mos.) in the ITT population. Additionally- m-DFS (not reached vs 8.4mos.) among patients whose tumors express PD-L1 ≥1% with a 45% reduction in risk of disease recurrence or death
  • The application was approved under the FDA’s RTOR pilot program. The results further support the conversion of Opdivo’s accelerated approval to regular approval

  Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions